Ji Y - Search Results

1

Prediction of pH-Dependent Drug-Drug Interactions for Basic Drugs Using Physiologically Based Biopharmaceutics Modeling: Industry Case Studies.

Mitra A, Parrott N, Miller N, Lloyd R, Tistaert C, Heimbach T, Ji Y, Kesisoglou F. Mitra A, et al. Among authors: ji y. J Pharm Sci. 2020 Mar;109(3):1380-1394. doi: 10.1016/j.xphs.2019.11.017. Epub 2019 Nov 25. J Pharm Sci. 2020. PMID: 31778721

2

Ribociclib Drug-Drug Interactions: Clinical Evaluations and Physiologically-Based Pharmacokinetic Modeling to Guide Drug Labeling.

Samant TS, Huth F, Umehara K, Schiller H, Dhuria SV, Elmeliegy M, Miller M, Chakraborty A, Heimbach T, He H, Ji Y. Samant TS, et al. Among authors: ji y. Clin Pharmacol Ther. 2020 Sep;108(3):575-585. doi: 10.1002/cpt.1950. Epub 2020 Jul 25. Clin Pharmacol Ther. 2020. PMID: 32557601 Clinical Trial.

3

Physiologically Based Biopharmaceutics Modeling to Demonstrate Virtual Bioequivalence and Bioequivalence Safe-space for Ribociclib which has Permeation Rate-controlled Absorption.

Laisney M, Heimbach T, Mueller-Zsigmondy M, Blumenstein L, Costa R, Ji Y. Laisney M, et al. Among authors: ji y. J Pharm Sci. 2022 Jan;111(1):274-284. doi: 10.1016/j.xphs.2021.10.017. Epub 2021 Oct 19. J Pharm Sci. 2022. PMID: 34678270

4

Evaluation of Absolute Oral Bioavailability and Bioequivalence of Ribociclib, a Cyclin-Dependent Kinase 4/6 Inhibitor, in Healthy Subjects.

Ji Y, Abdelhady AM, Samant TS, Yang S, Rodriguez Lorenc K. Ji Y, et al. Clin Pharmacol Drug Dev. 2020 Oct;9(7):855-866. doi: 10.1002/cpdd.853. Epub 2020 Jul 24. Clin Pharmacol Drug Dev. 2020. PMID: 32706937 Clinical Trial.

5

Ribociclib Population Pharmacokinetics and Pharmacokinetic/Pharmacodynamic Analysis of Neutrophils in Cancer Patients.

Lu Y, Yang S, Ho YY, Ji Y. Lu Y, et al. Among authors: ji y. J Clin Pharmacol. 2021 Aug;61(8):1054-1068. doi: 10.1002/jcph.1856. Epub 2021 Apr 17. J Clin Pharmacol. 2021. PMID: 33713359 Clinical Trial.

6

Exploratory Food Effect Assessment in Patients in Early Clinical Development of Oncology Drugs.

Ji Y, Tan E, Hengelage T, Quinlan M, Hendriks BS. Ji Y, et al. Clin Pharmacol Ther. 2023 Aug;114(2):288-302. doi: 10.1002/cpt.2911. Epub 2023 May 26. Clin Pharmacol Ther. 2023. PMID: 37078098 Review.

7

Species-dependent hepatic and intestinal metabolism of selective oestrogen receptor degrader LSZ102 by sulphation and glucuronidation.

Pearson D, Jin Y, Romeo A, Birlinger BL, Schiller H, Ji Y, Gunduz M, Baldoni D, Walles M. Pearson D, et al. Among authors: ji y. Xenobiotica. 2022 Jan;52(1):26-37. doi: 10.1080/00498254.2022.2037027. Epub 2022 Feb 10. Xenobiotica. 2022. PMID: 35098863

8

Model-informed drug development for immuno-oncology agonistic anti-GITR antibody GWN323: Dose selection based on MABEL and biologically active dose.

Ji Y, Knee D, Chen X, Dang A, Mataraza J, Wolf B, Sy SKB. Ji Y, et al. Clin Transl Sci. 2022 Sep;15(9):2218-2229. doi: 10.1111/cts.13355. Epub 2022 Jul 19. Clin Transl Sci. 2022. PMID: 35731955 Free PMC article.

9

Pharmacokinetics of Ribociclib in Subjects With Hepatic Impairment.

Samant TS, Yang S, Miller M, Ji Y. Samant TS, et al. Among authors: ji y. J Clin Pharmacol. 2021 Aug;61(8):1001-1009. doi: 10.1002/jcph.1825. Epub 2021 Mar 12. J Clin Pharmacol. 2021. PMID: 33555033 Clinical Trial.

10

Model-based dose selection to inform translational clinical oncology development of WNT974, a first-in-class Porcupine inhibitor.

Ji Y, Huang PH, Woolfenden S, Myers A. Ji Y, et al. Clin Transl Sci. 2022 Jul;15(7):1713-1722. doi: 10.1111/cts.13287. Epub 2022 May 27. Clin Transl Sci. 2022. PMID: 35620969 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

11,068 results

Search Page

Filters